Aytu BioPharma, Inc.
AYTU Healthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.
Follow AYTU
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
26.31 | 26.72 | 30.03 | 32.63 |
+8 more quarters Free account |
Receivables |
22.78 | 24.49 | 30.92 | 33.23 | |
Inventory |
6.86 | 7.46 | 8.66 | 10.10 | |
Total current assets |
61.76 | 67.33 | 76.24 | 81.11 | |
Property, Plant, Equpment (Net) |
0.39 | 0.41 | 0.48 | 0.50 | |
Goodwill and Intangible Assets (Total) |
41.40 | 42.49 | 43.58 | 41.43 | |
Long-term assets (Other) |
0.60 | 0.56 | 0.74 | 0.94 | |
Total non-current assets |
43.25 | 44.36 | 45.76 | 43.88 | |
Total Assets |
105.01 | 111.69 | 122.00 | 124.99 | |
Accounts Payable |
11.28 | 13.21 | 14.26 | 12.34 | |
Accrued Expenses |
35.21 | 34.27 | 40.16 | 36.70 | |
Current Part of Debt |
7.93 | 12.27 | 10.93 | 16.73 | |
Other current liabilities |
0.24 | 0.22 | 0.22 | 0.22 | |
Total current liabilities |
54.66 | 59.97 | 65.56 | 65.99 | |
Long Term Debt (Total) |
9.10 | 9.55 | 10.00 | 10.45 | |
Non-current Liabilities (Other) |
5.97 | 7.03 | 32.24 | 25.38 | |
Total non-current liabilities |
15.07 | 16.57 | 42.24 | 35.82 | |
Total liabilities |
69.73 | 76.55 | 107.80 | 101.82 | |
Additional Paid In Capital |
383.06 | 382.91 | 356.35 | 354.74 | |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | |
Retained Earnings |
(347.79) | (347.77) | (342.15) | (331.57) | |
Common Equity (Total) |
35.27 | 35.14 | 14.20 | 23.17 | |
Shareholders Equity (Total) |
35.27 | 35.14 | 14.20 | 23.17 | |
Shareholders Equity and Liabilities (Total) |
105.01 | 111.69 | 122.00 | 124.99 | |
Shares (Common) |
10.73 | 10.73 | 10.73 | 9.91 | |
Shareholders Equity (Tangible) |
(6.13) | (7.35) | (29.38) | (18.26) | |
Net Debt |
(9.28) | (4.90) | (9.09) | (5.45) | |
Total Debt |
17.03 | 21.82 | 20.93 | 27.18 |